The latest discoveries in Neurology
A concise briefing on the most relevant research developments in your field, curated for clarity and impact.
A blood test for Alzheimer’s gets a crucial upgrade
A new study demonstrates that a simple blood test combining two key Alzheimer’s biomarkers—phosphorylated tau 217 and amyloid-beta 1-42—outperforms using either marker alone. The research, published in *Brain*, shows that the ratio of pTau217 to Aβ1-42 in plasma can identify amyloid pathology with high accuracy (positive and negative predictive values over 94%). Crucially, this dual-marker approach significantly reduces the number of patients who would receive an inconclusive “indeterminate” result, making the test more clinically actionable for diagnosing Alzheimer’s disease.
Why it might matter to you:
This work directly advances the goal of developing clinically actionable, blood-based diagnostic assays for neurodegenerative disease. By reducing diagnostic uncertainty, the pTau217/Aβ1-42 ratio could streamline patient pathways and improve the utility of blood biomarkers in clinical trials. For your work on correlating biomarkers with multimodal data, this refined assay provides a more reliable and scalable tool for linking molecular pathology with imaging and clinical outcomes.
Stay curious. Stay informed — with
Science Briefing.
Always double check the original article for accuracy.
